Jiménez-Alcaide, 1,349 patient various antiandrogen prophylaxis study: 33% lower mortality [p=0.41], 8% higher progression [p=0.77], and 68% more cases [p=0.15] https://c19p.org/jimenezalcaide
copied to clipboard
Influence of androgen deprivation therapy on the severity of COVID‐19 in prostate cancer patients
et al., The Prostate, doi:10.1002/pros.24232
Retrospective 1,349 prostate cancer patients in Spain, 156 on ADT, showing no significant differences in COVID-19 outcomes with treatment.
|
risk of death, 33.0% lower, RR 0.67, p = 0.41, treatment 3 of 11 (27.3%), control 17 of 50 (34.0%), adjusted per study, multivariable.
|
|
risk of progression, 8.0% higher, RR 1.08, p = 0.77, treatment 11, control 50, adjusted per study, multivariable.
|
|
risk of case, 68.2% higher, RR 1.68, p = 0.15, treatment 11 of 156 (7.1%), control 50 of 1,193 (4.2%), excluded in exclusion analyses:
excessive unadjusted differences between groups.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Jiménez-Alcaide et al., 13 Sep 2021, retrospective, Spain, peer-reviewed, 9 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.